Press

HAVN Life Announces Retail Listing With Loblaws Company Ltd

Oct 29 • 3 min read

HAVN Life Sciences Inc. (CSE: HAVN | OTC: HAVLF | FSE: 5NP), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that it has secured a product listing with Canada’s largest grocery retailer, Loblaws Company Ltd (LCL) for the Company’s line of natural health products. Havn Life previously…

Seelos Therapeutics to Sponsor and Participate in Wonderland, the World’s Leading Psychedelic Event

Oct 27 • 2 min read

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will sponsor and participate in Wonderland, the World’s Leading Psychedelic Event, organized by Microdose Psychedelics Insights, to be held at the Mana Wynwood Convention Center in Miami, FL from November 3rd to the…

Cybin’s EMBARK Program Announces Graduation of Facilitators

Oct 27 • 4 min read

Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics®”, today announced the graduation of highly-skilled facilitators from its EMBARK Psychedelic-Assisted Psychotherapy Training Program. EMBARK is a leading-edge model of psychedelic-assisted psychotherapy co-developed by Alex Belser, Ph.D., and Bill Brennan, Ph.D. The EMBARK model is currently being implemented in two clinical-stage trials,…

Wellbeing Announces Dfinitive Agreement to Divest IRP Health

Oct 27 • 3 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that it has entered into a definitive agreement under which Pathway Health Corp. will acquire all or substantially all…

Delic Labs President and CSO Dr. Markus Roggen to Discuss the Importance of R&D for Business Growth at MJBizCon

Oct 27 • 2 min read

Delic Holdings Corp (CSE: DELC | OTCQB: DELCF | FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding Delic Labs President and CSO Dr. Markus Roggen’s participation at the 11th annual MJBizCon in Las Vegas, Nevada on November 15, 2022. MJBizScience SymposiumNovember 15, 2022With over 1,400 exhibitors, 35,000 attendees and countless networking opportunities, MJBizCon…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441